• +1-646-491-9876
    • +91-20-67278686

    Search

    Beta Nerve Growth Factor-Pipeline Review H1 2017

    Beta Nerve Growth Factor-Pipeline Review H1 2017

    • Report Code ID: RW0001834357
    • Category Pharmaceuticals
    • No. of Pages 59
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2017

    Summary

    Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The latest report Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2017, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 5 and 1 respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Toxicology which include indications Osteoarthritis Pain, Alzheimer's Disease, Cancer Pain, Low Back Pain, Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, Diabetic Neuropathy, Huntington Disease, Interstitial Cystitis (Painful Bladder Syndrome) , Keratitis, Mild Cognitive Impairment, Optic Nerve Injury, Peripheral Nerve Injury and Post-Operative Pain.

    Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
    - The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
    Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
    Amgen Inc
    Astellas Pharma Inc
    Fujimoto Pharmaceutical Corp
    Krenitsky Pharmaceuticals Inc
    MedImmune LLC
    NsGene A/S
    Pfizer Inc
    Regeneron Pharmaceuticals Inc
    Serometrix LLC
    Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
    AS-288640100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-6294 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fasinumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fulranumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate NGF for Optic Nerve Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KP-544 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-7352 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NsG-0202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RBM-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Neurotrophic Keratitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit NGF for Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tanezumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
    Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
    Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
    Featured News & Press Releases
    Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
    May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
    Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain
    Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
    Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors
    Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909
    Dec 27, 2010: FDA Halts Development Of Regeneron's Pain Drug
    Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program
    Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab
    May 12, 2010: Regeneron Provides Initial Data On REGN475
    Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010
    Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202
    Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx
    Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains
    Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer's Disease
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Amgen Inc, H1 2017
    Pipeline by Astellas Pharma Inc, H1 2017
    Pipeline by Fujimoto Pharmaceutical Corp, H1 2017
    Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
    Pipeline by MedImmune LLC, H1 2017
    Pipeline by NsGene A/S, H1 2017
    Pipeline by Pfizer Inc, H1 2017
    Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Pipeline by Serometrix LLC, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Amgen Inc
    Astellas Pharma Inc
    Fujimoto Pharmaceutical Corp
    Krenitsky Pharmaceuticals Inc
    MedImmune LLC
    NsGene A/S
    Pfizer Inc
    Regeneron Pharmaceuticals Inc
    Serometrix LLC

    Request for Sample

    Report Url http://www.reportsweb.com//beta-nerve-growth-factor-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//beta-nerve-growth-factor-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//beta-nerve-growth-factor-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments